New Limit Transitions to R&D and Accelerates Drug Mass Production
jacobkimmel · x · 2026-07-11
Anti-aging research company New Limit announced its transition from a pure research institution to a true R&D organization, currently building development teams and hiring for multiple roles. To advance its first clinical trials, the company needs to scale up candidate drug manufacturing by roughly 1000 times. Over the past two months, the team has successfully achieved a capacity increase of over 120x and established its first potency assay.
More from Companies & People
- This week’s NYC AI events include Cerebras, Google DeepMind, and a Physical AI hackathon — round · 2026-07-21
- Opendoor CEO shares a raw turnaround playbook in a rare live interview — morganb · 2026-07-21
- A market map tracks outpatient healthcare agentic AI across front, back and mid office — HealthcareAIGuy · 2026-07-21
- FutureCaribbean’s Buildathon offers $50K, H200 compute, and an NYSE pitch — HeyAmit_ · 2026-07-21
- Reliability is a discipline, not a one-time milestone for engineering teams — rseroter · 2026-07-21
- Cloud giants are winning enterprise agentic AI as enterprises buy trust, not features — DavidLinthicum · 2026-07-21